Thursday 6 May 2021
Home      All news      Contact us      RSS      English
Thaipr - 25 days ago

Airway Therapeutics Announces FDA Acceptance of IND for AT-100 s Second Indication in Severe COVID-19 Patients

Initiating Phase 1b clinical trial with initial results expected 3Q2021 Potential for novel therapeutic AT-100 to inhibit viral replication, promote viral elimination and reduction of lung injury, inflammation, and secondary infections in severe COVID-19 patients Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation [ ] The post Airway Therapeutics Announces FDA Acceptance of IND for AT-100 s Second Indication in Severe COVID-19 Patients appeared first on ThaiPR.NET.


Latest News
Hashtags:   

Airway

 | 

Therapeutics

 | 

Announces

 | 

Acceptance

 | 

Second

 | 

Indication

 | 

Severe

 | 

COVID

 | 

Patients

 | 

Sources